Why this story
- Why it matters
- The early results give researchers a reason to test whether adding the drug to first-line chemotherapy improves outcomes in metastatic pancreatic cancer.
- Attention gap
- Ori’s seven-day headline-index search recorded no matches among 11 outlets. The publisher read the sponsor’s results and ecancer’s symposium report. These sources describe the same conference data. The recorded count reflects the limits of Ori’s search.
A study presented in Barcelona on November 20 reported that 60.7% of 61 people with previously untreated metastatic pancreatic cancer had a confirmed tumor response after receiving daraxonrasib with gemcitabine and nab-paclitaxel. Revolution Medicines, the sponsor, reported a median follow-up of 18.3 months.
The study estimated that 76.6% of participants were alive at one year. The estimate’s 95% confidence interval ran from 63.7% to 85.4%. Everyone received the combination, leaving open how much daraxonrasib contributed to either tumor shrinkage or survival.
What the evidence cannot tell us
- Small, sponsor-reported, single-arm phase 1/2 conference results. Survival estimates can change with longer follow-up.
What to watch
Randomized comparisons can show whether the combination improves survival over chemotherapy alone.
Read the sources. Credit the work.
The reporting and documents behind this brief, linked directly to the source. Verified publisher and author credits appear where available; other entries show their actual website address. Several links may draw on the same underlying reporting or research.
Revolution Medicines (press release)
Updated Phase 1/2 Data for RASONQUE (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026 (opens in a new tab)ir.revmed.com · November 19, 2026
Primary document / sourceContent read for this publication · November 22, 2026Publisher credit checked November 22, 2026. View credit on the source page (opens in a new tab).
ecancer
EORTC 2026: Metastatic pancreatic cancer responds well to initial treatment with combination of daraxonrasib and chemotherapy (opens in a new tab)ecancer.org · November 20, 2026
Reporting / analysisContent read for this publication · November 22, 2026Publisher credit checked November 22, 2026. View credit on the source page (opens in a new tab).
This story was written and checked using AI against the linked evidence. No routine human review is claimed. Read the method.
Suggest an update or correctionPublished corrections